The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
The company expects meaningful revenue contribution from this long-term agreement
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Subscribe To Our Newsletter & Stay Updated
